GCP
KROS icon

GSA Capital Partners’s Keros Therapeutics KROS Stock Holding History

GSA Capital Partners’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-51,346
Closed -$1.04M – 1966
2025
Q4 		$1.04M Buy
51,346
+26,046
+103% +$457K 0.09% 337
2025
Q3 		$400K Sell
25,300
-36,155
-59% -$534K 0.03% 1004
2025
Q2 		$820K Buy
+61,455
New +$830K 0.06% 582
2025
Q1 		– Sell
-11,158
Closed -$177K – 1879
2024
Q4 		$177K Buy
+11,158
New +$580K 0.01% 1441
2024
Q2 		– Sell
-8,538
Closed -$565K – 1855
2024
Q1 		$565K Buy
8,538
+1,736
+26% +$103K 0.04% 801
2023
Q4 		$270K Sell
6,802
-10,359
-60% -$325K 0.02% 1170
2023
Q3 		$547K Buy
+17,161
New +$641K 0.05% 736
2023
Q2 		– Sell
-18,324
Closed -$782K – 1743
2023
Q1 		$782K Buy
18,324
+10,151
+124% +$513K 0.08% 454
2022
Q4 		$392K Buy
+8,173
New +$382K 0.05% 755

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

GSA Capital Partners's KROS Position: Q1 2026 in Review

GSA Capital Partners sold out of Keros Therapeutics (KROS) in Q1 2026, closing a stake of 51,346 shares — an estimated $1.04M sold.

GSA Capital Partners first reported a position in KROS in Q4 2022 and held it in 9 quarters. The position peaked at $1.04M in Q4 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • GSA Capital Partners reported no remaining Keros Therapeutics position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 51,346 Keros Therapeutics shares in Q1 2026, an estimated $1.04M.
  • GSA Capital Partners first reported a position in Keros Therapeutics in Q4 2022 and held it in 9 quarters.
  • GSA Capital Partners's Keros Therapeutics position peaked at $1.04M in Q4 2025.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.